IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2011;4(4):371-377

Original Ariticle
Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with
unfavorable prognosis but not with an NPM1 or KIT mutation

Faisal M. Alseraye, Zhuang Zuo, Carlos Bueso-Ramos, Sa Wang, L. Jeffrey Medeiros, Gary Lu

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Received April 3, 2011; accepted April 19, 2011; Epub April 25, 2011; published April 30, 2011

Abstract: Papillary thyroid cancer (PTC) has an impressive propensity for lymphatic spread. Signal transducers and activators of transcription 3
(STAT3), constitutively activated in many tumors, may help stratify risk of metastases in PTC and assist clinicians in selecting patients best
suited for aggressive therapy. We examined 49 patients with PTC, 22 with and 27 without lymphatic metastases. All patients had a total
thyroidectomy with lymph node dissection to document true node negative cases. The level of STAT3 expression in benign thyroid tissue is
barely detectable by immunohistochemistry. Only 11 of the 35 specimens exhibited weak immunostaining for STAT3, and pSTAT3 was found
weakly positive in 3 of 35 benign specimens. In primary PTC tumors, node negative cases (n=22) significantly differed from node positive
cases (n=19) regarding pSTAT3 expression: while only 4 of 22 (18%) cases in the node-negative group were weakly (1+) positive for pSTAT3,
12 of 19 (58%) cases in the node-positive group were positive (p=0.011, Fisher exact test) with 45% of these specimens exhibiting strong (2+)
staining. Expression of STAT3 was seen in 100% of node-positive primary tumors (19/19) and 98% of node-negative tumors (21/22). There
was no difference in staining intensity for STAT3 where strong (2+) staining was seen 12/19 node-positive tumors and 13/22 node-negative
tumors (p=1). The STAT3 pathway is ubiquitous in PTC and activated pSTAT3 is significantly more specific in discriminating PTC with
metastatic potential from local disease. This is the first study that documents the role of activated pSTAT3 in lymphatic metastases in thyroid
cancer. (IJCEP1104006)

Keywords: STAT3, immunohistochemistry, metastases, papillary thyroid cancer

Full text PDF

Address all correspondence to:
Gary Lu, MD
Department of Hematopathology, Box 350
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030, USA.
Tel: 713-563-4369; Fax: 713-745-3215